Universität zu Köln

Brueckl, Wolfgang Michael, Al-Batran, Salah-Eddin, Ficker, Joachim Hans, Claas, Silke, Atmaca, Akin, Hartmann, Arndt, Rieker, Ralf Joachim and Wirtz, Ralph Markus (2013). Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. Int. J. Cancer, 133 (8). S. 1825 - 1832. HOBOKEN: WILEY. ISSN 1097-0215

Full text not available from this repository.

Abstract

Adjuvant chemotherapy (ACT) leads to a modest improvement in survival among patients with completely resected non-small cell lung cancer (NSCLC) but molecular predictors are still rare. Publicly available gene microarray, clinical and follow-up data from two different studies on early-stage NSCLC were used to determine the expression of estrogen receptor 1 (ESR1). Expression values were calculated against clinical and survival data in a training set (n = 138) and a test set (subpopulation from the adjuvant JBR.10 study) allowing the determination of the prognostic effect of ESR1 in the observational arm as well as the predictive effect of ESR1 regarding ACT. Data were well balanced in terms of ESR1 expression. ESR1 high expression was of significant positive prognostic value in the training set and this could be confirmed in the test set cohort (hazard ratio for overall survival 0.248, 95% confidence interval: 0.088-0.701; p = 0.008). Additionally, ESR1 low tumors showed a benefit from ACT in terms of 5-year survival (33.3% observation arm and 77.8% ACT arm; p = 0.003), whereas patients with ESR1 high tumors did not have any benefit from ACT (test of interaction p = 0.024). ESR1 is an independent positive prognostic factor for survival in early-stage NSCLC patients. Patients with ESR1 high tumors did not benefit from ACT. What's new? While non-small cell lung cancer (NSCLC) patients are at a high risk of tumor relapse in spite of curative resection and also adjuvant chemotherapy, some remain relapse-free even with no adjuvant chemotherapy. Prognostic and predictive markers are therefore of utmost importance for an adequate therapeutic strategy. The authors show for the first time that estrogen receptor 1 (ESR1) expression in NSCLC is of prognostic value and might be predictive of the benefit of adjuvant chemotherapy. If the results are confirmed, ESR1 expression could help stratify NSCLC patients into different prognostic groups and inform decision-making regarding the use of adjuvant chemotherapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Brueckl, Wolfgang Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Al-Batran, Salah-Eddin UNSPECIFIED UNSPECIFIED UNSPECIFIED Ficker, Joachim Hans UNSPECIFIED UNSPECIFIED UNSPECIFIED Claas, Silke UNSPECIFIED UNSPECIFIED UNSPECIFIED Atmaca, Akin UNSPECIFIED UNSPECIFIED UNSPECIFIED Hartmann, Arndt UNSPECIFIED UNSPECIFIED UNSPECIFIED Rieker, Ralf Joachim UNSPECIFIED UNSPECIFIED UNSPECIFIED Wirtz, Ralph Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-474004
DOI:	10.1002/ijc.28209
Journal or Publication Title:	Int. J. Cancer
Volume:	133
Number:	8
Page Range:	S. 1825 - 1832
Date:	2013
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1097-0215
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CISPLATIN COMBINATION CHEMOTHERAPY; VINORELBINE PLUS CISPLATIN; IMMUNOHISTOCHEMICAL EXPRESSION; MESSENGER-RNA; PROGESTERONE-RECEPTORS; ADJUVANT CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; KINETIC PCR; PHASE-II; BETA Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47400